SYNAGIS CPT Drug Code: 90378

Drug & Product Overview

HCPCS Descriptor Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each

Manufacturer Sobi

Route of Administration Intramuscular

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About SYNAGIS

Synagis is a medication aligned to the HCPCS CPT Drug Code: 90378 for billing, pricing, and reimbursement purposes in the United States. It is a Vaccine drug administered via the intramuscular route and manufactured by Sobi.

Manufacturers, reach out to us to add more information.

NDC Code Information

2 NDC packages are crosswalked to 90378. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	SYNAGIS
	SYNAGIS

Login to view 2 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

SYNAGIS CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

CMS does not include Synagis (90378) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing 90378. Wastage billing guide →

SYNAGIS Medically Unlikely Edits (MUE)

The most billing units of 90378 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 50mg.

Practitioner Office & Hospital Outpatient

4 units / day

= 200 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

SYNAGIS Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk.

Drug Class

AntibodiesMonoclonal [CS]Fusion Protein Inhibitors [MoA]Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]

Frequently Asked Questions

Is there an available Synagis billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for SYNAGIS.

Are there any available Synagis patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for SYNAGIS.

Where can I find Synagis prescribing information?

SYNAGIS prescribing information can be found at the link below: Visit Here →

Where can I find Synagis side effect information?

Information regarding SYNAGIS's side effects can be found at MedlinePlus Visit Here →

Does billing SYNAGIS require JZ/JW wastage modifiers?

CMS does not include SYNAGIS (90378) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing 90378. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.